Published on in Vol 7, No 2 (2021): Apr-Jun
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/25800, first published
.
![Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non–Muscle-Invasive Bladder Cancer: Retrospective Cohort Study Clinicopathological Criteria Predictive of Recurrence Following Bacillus Calmette-Guérin Therapy Initiation in Non–Muscle-Invasive Bladder Cancer: Retrospective Cohort Study](https://asset.jmir.pub/assets/d5c83fa8fe0fc02eb8b01b801cb4da9c.png 480w,https://asset.jmir.pub/assets/d5c83fa8fe0fc02eb8b01b801cb4da9c.png 960w,https://asset.jmir.pub/assets/d5c83fa8fe0fc02eb8b01b801cb4da9c.png 1920w,https://asset.jmir.pub/assets/d5c83fa8fe0fc02eb8b01b801cb4da9c.png 2500w)
Journals
- Radovanovic M, Petrovic M, Santric V, Zubelic A. Predictors of response to BCG therapy in non-muscle invasive bladder cancer. Srpski arhiv za celokupno lekarstvo 2022;150(1-2):113 View
- Kim J, Lee D, Song W, Lee S, Park S, Nam J. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer. Investigative and Clinical Urology 2022;63(5):531 View
- Semeniuk-Wojtaś A, Poddębniak-Strama K, Modzelewska M, Baryła M, Dziąg-Dudek E, Syryło T, Górnicka B, Jakieła A, Stec R. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy 2023;72(7):1971 View
- Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock R. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Frontiers in Oncology 2023;13 View